Here are three things to know.
- The Auvi-Q 0.1 milligram auto-injector is intended to treat infants and young children who weigh 16.5 to 33 pounds and are at risk for serious allergic reactions.
- The device contains a shorter needle and lower epinephrine dose than other Auvi-Q auto-injectors already on the market.
- Kaléo expects Auvi-Q 0.1 milligram to be available for patients by mid-2018.
More articles on supply chain:
4 ways the FDA is addressing the saline bag shortage
FDA approves first pill with digital ingestion tracking system
Mylan lays off up to 300 employees
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
